Remdesivir is a drug developed by Gilead Sciences. The drug is a nucleoside analog with antiviral activity. In HAE cells, the EC50 value of SARS-CoV and MERS-CoV is 74 nM , In delayed brain tumor cells, the EC50 value of mouse hepatitis virus is 30 nM.
On October 22, 2020, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences' antiviral drug Remdesivir for the treatment of hospitalized patients with COVID-19, becoming the first officially approved treatment for COVID-19 in the United States.
Betadex sulfobutyl ether sodium is used in the formulation as a solubilizing agent due to the limited aqueous solubility of remdesivir as the main excipient.
The study shows that Betadex sulfobutyl ether sodium is one of the best solubility enhancers. It has been videly used for the formulation of drugs with poor water solubility . It formed non-covalent, dynamic, water soluble inclusion complexes.
Betadex sulfobutyl ether sodium performed as a hydrophilic carrier for drugs showing inadequate molecular characteristics for complexation,and hence improving aqueous solubility of the drugs and dissolution rate.
Also another suggested mechanism for improving solubility and dissolution rate is that upon complexation with Betadex sulfobutyl ether sodium reduction of crystallinity or amorphization take place.
Shandong Binzhou Zhiyuan Biotechnology Co., Ltd, as the main manufacture of Injection grade Betadex sulfobutyl ether sodium in China, is fighting against the COVID-19 with worldwide people by proving high quality Betadex sulfobutyl ether sodium product,and will continue to develop more and more effective product to service for the human's health.